Insulet’s Omnipod® Horizon™ Hybrid Closed-Loop System Improves Glycemic Control in Patients as Young as Two Years Old with Type 1 Diabetes


ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that positive results from the most recent clinical trial of the Omnipod® Horizon™ Automated Insulin Delivery System (Omnipod Horizon System) were presented during the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, California. The study demonstrated


Read More: